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Background: The peroxisome proliferator-activated receptors (PPAR) are the nuclear
hormone receptor superfamily of ligand-activated transcriptional factors. PPAR-gamma (PPARG)
activation downregulates production of Th2 type cytokines and eosinophil function. Addition-
ally, treatment with a synthetic PPARG ligand can reduce lung inflammation and IFN-gamma,
IL-4, and IL-2 production in experimental allergic asthma. In patients with asthma, PPARG gene
expression is known to be associated with the airway inflammatory and remodeling responses.
Thus, genetic variants of PPARG may be associated with the development of asthma.
Methods: We genotyped two single nucleotide polymorphisms on the PPARG gene, þ34C>G
(Pro12Ala) and þ82466C> T (His449His), in Korean subjects (839 subjects with asthma and
449 normal controls).
Results: Association analysis using logistic regression analysis showed that þ82466C> T
and haplotypes 1(CC) and 2(CT) were associated with the development of asthma (pZ 0.01e
0.04). The frequency of PPARG-ht2 was significantly lower in the patients with asthma compared
to the normal controls in codominant and dominant models (pZ 0.01, pcorrZ 0.03 and pZ 0.02,
pcorrZ 0.03, respectively). Conversely, the frequency of PPARG-ht1 was significantly higher inllergy and Respiratory Medicine, Department of Internal Medicine, Soonchunhyang University Bucheon
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þ34C>G
þ82466C> Tthe patients with asthma compared to the normal controls in the codominant model [pZ 0.04,
OR: 1.27 (1.01e1.6)]. In addition, the rare allele frequency of þ82466C> T was significantly
lower in patients with asthma in comparison to normal controls in the codominant model (OR:
0.78, pZ 0.04). Thus, polymorphism of the PPARG gene may be linked to an increased risk of
asthma development.
ª 2009 Elsevier Ltd. All rights reserved.Introduction
The peroxisome proliferator-activated receptors (PPAR)
are the nuclear hormone receptor superfamily of ligand-
activated transcriptional factors, which include receptors
for steroids, thyroid hormone, vitamin D, and retinoic
acid.1 Three subtypes of PPAR are known, PPAR-alpha,
PPAR-delta, and PPAR-gamma (PPARG). PPARG (MIM#
601487), located on chromosome 3p25, was originally
characterized as a regulator of adipocyte differentiation
and lipid metabolism,2 and of cellular turnover.3 In addi-
tion, PPARG activation has been known to downregulate
the synthesis and release of immune modulating cytokines
from various cell types.4 That a range of naturally occur-
ring substances, including the metabolites of arachidonate
pathway, such as 15-hydroxyeicosatetranoic acid (15-
HETE), or Th2 cytokines, such as IL-4, are potent inducers
of PPARG expression has been well established.5 In
contrast, stimulation of the PPARG ligand was found to
significantly inhibit production of the Th2 type cytokines
and downregulate eosinophil functions.6,7 Additionally,
treatment with a synthetic PPARG ligand can reduce lung
inflammation and IFN-gamma, IL-4, and IL-2 production in
experimental allergic asthma.8 In subjects with asthma,
PPARG expression is known to be associated with the
airway inflammatory and remodeling responses.9 Thus,
genetic variants of the PPARG gene may be associated with
the development of asthma.
Recently, Palmer et al. reported that PPARG gene
polymorphisms were associated with the risk of asthma
exacerbation in Caucasian populations.10 The homozygous
haplotype combination of þ34C>G (Pro12Ala) was asso-
ciated with an increased risk for asthma exacerbation.10
However, to the best of our knowledge, no previous study
has analyzed potential associations between the two
common polymorphisms of the PPARG gene, þ34C>G
(Pro12Ala) and þ82466C> T (His449His), with the risk of
asthma.notyping of SNPs on PPARG gen
Region Primer sequenc
Exon3 GTTATGGGTGA
GCAGACAGTGT
ATTGACCCAGA
ATTGACGCAGA
Exon8 CAGAAAATGAC
CGTCTTCTTGA
CTGCACGTGTT
CTGCACATGTTMaterials and methods
Subjects
The subjects were recruited from the Asthma Genome
Research Center, which consists of Soonchunhyang University
hospitals in Bucheon, Seoul, and Chunan, Korea. All of the
subjects were Korean. A clinical historywas obtained for each
patient using a physician-administered questionnaire.11 And
the patients with asthma had compatible clinical symptoms
and physical characteristics.12 Each patient showed airway
reversibility [as documented by inhalant bronchodilator-
induced improvement of more than 15% of forced expiratory
volume in 1 s (FEV1)] and/or airway hyperreactivity of less
than 10 mg/ml of methacholine. Normal controls (nZ 449)
were recruited from spouses of the patients or members of
the general population who answered negatively to
a screening questionnaire regarding respiratory symptoms.11
The controls had FEV1 values> 80% predicted, PC20 meth-
acholine> 10 mg/ml, and normal findings on simple chest
radiograms. Skin prick tests were performed with 24 common
aeroallergens.13 Atopy was defined as one or more positive
reactions (>3 mm in diameter or greater than histamine
reaction of 1 mg/ml) on the skin prick test. Total IgE was
measured using the UniCAP system (Pharmacia Diagnostics,
Uppsala, Sweden). The subjects with diabetes mellitus were
excluded because the PPARG polymorphism was reported to
be associated with the development of diabetes mellitus
in Korea.14 All subjects gave written informed consent to
participate in the study, and the protocols were approved by
the local ethics committees.
Genotyping of the single nucleotide polymorphism
(SNPs) on the PPARG gene
For genotyping of polymorphic sites, amplifying primers and
probes were designed for TaqMan (Table 1) and the singlee.
e Orientation Location
AACTCTGGGAGATT Forward 3/þ22
ATCAGTGAAGGAAT Reverse þ44/þ68
AAG VIC þ23/þ41
AAG FAM
AGACCTCAGACAGA Forward þ824271/þ82442
TCACCTGCAGTAG Reverse þ82463/þ82486
CCG VIC þ82449/þ82462
CCG FAM
Table 2 The clinical profiles of the study subjects.
Normal controls Asthmatics p-Value
Number 449 839 e
Age [year (range)] 44 (5e80) 46 (8e80) 0.369
Duration [year (range)] e 4 (1e70) e
On set of age [year (range)] e 38 (1e76) e
Sex (male,%) 40.31 39.57 0.796
Smoker/ex-smoker (%) 17.16/10.53 16.21/16.21 0.022
Atopy (%) 35.15 60.22 <0.0001
FVC (% predicted) 94.24 0.59 83.51 0.62 <0.0001
FEV1 (% predicted) 104.14 0.72 79.63 0.76 <0.0001
log [PC20 methacholine] (mg/ml) 1.39 0.002 0.17 0.02 <0.0001
BMI (kg/m2) 23.81 0.16 24.19 0.12 0.073
Blood eosinophil (%) 2.37 0.1 5.61 0.19 <0.0001
log [total IgE] (IU/ml) 1.66 0.03 2.17 0.02 <0.0001
Values are mean S.E.
P-values are obtained using t-test or c2 test between asthmatics and normal controls.
1022 S.-H. Oh et al.base extension method. Primer Express (Applied Biosystems,
Foster City, CA, USA) was used to design both the PCR
primers and the MGB TaqMan probes. One allelic probe was
labeled with the FAM dye and the other with the fluorescent
VIC dye. Typically, PCR was run in the TaqMan Universal
Master mixture without UNG (Applied Biosystems) at
a primer concentration of 900 nM and TaqMan MGB-probe
concentration of 200 nM. The reaction was performed in
a 384-well format in a total reaction volume of 5 ml using
20 ng of genomic DNA. The plate was then placed in
a thermal cycler (PE 9700; Applied Biosystems) and heated
for 2 min at 50 C and for 10 min at 95 C, followed by 40
cycles at 95 C for 15 s and 60 C for 1 min. The TaqMan assay
plate was then transferred to a Prism 7900 HT instrument
(Applied Biosystems), where the fluorescence intensity of
each well was read. Fluorescence data files from each plate
were analyzed by automated software (SDS 2.1).
Statistics
We applied the widely used Lewontin’s D0 (jD0j) and R2
measures of linkage disequilibrium to all pairs of biallelic
loci.15 Haplotype associations were estimated using
HaploScore (http://www.biostat.wustl.edu/genetics/
geneticssoft/), which computes score statistics to test for
associations between a given haplotype and a wide variety
of traits, including binary, ordinal, quantitative, and
Poisson. The genetic effects of the haplotypes were
analyzed in the same way as the SNPs. The distributions of
the PPARG SNP genotypes and haplotypes among the
subjects with asthma and the normal subjects were
analyzed with logistic regression models that controlled forTable 3 The frequencies, heterozygosity and HardyeWeinberg
Gene Loci rs SNP Region A.A change Gen
C/C
PPARG þ34C>G rs 1801282 Exon3 Pro12Ala 118
þ82466C> T rs 3856806 Exon8 His449His 89
C/C, C/R and C/C represent common allele, heterozygosity and rare
*p-Values of deviation from HardyeWeinberg Equilibrium in the studyage (continuous value), sex (maleZ 0, femaleZ 1), atopy
status (non-atopyZ 0, atopyZ 1), body mass index (BMI;
continuous value) and smoking status (non-smokerZ 0, ex-
smokerZ 1, smokerZ 2) as covariables. The data were
managed and analyzed using SPSS ver. 10.0 (SPSS Inc.,
Chicago, IL, USA) software packages. A p 0.05 was
regarded as statistically significant. For correction of
multiple testing, the effective number of independent
markers in PPARG was calculated using the software
SNPSpD (http://genepi.qimr.edu.au/general/daleN/SNPSpD),
which is based on the spectral decomposition (SpD) of
matrices of pairwise linkage disequilibrium (LD) between
SNPs.16 The number of independent marker loci in PPARG
was calculated as 1.8712, and this was applied to correct
for multiple testing (p-value 1.8712). Statistical powers
were calculated using the Statistical Power Calculator
(http://www.dssresearch.com/toolkit/spcalc/power_p2.asp).
A two-tailed test was used on allele frequencies for both case
and control subjects at a 5% alpha level.
Results
Characteristics of the study subjects
Significant differences were observed in the smoking status
and prevalence of atopy between the controls and subjects
with asthma (Table 2). The FEV1% and PC20 methacholine
values of the patients with asthma were significantly lower
than those of the normal controls, whereas the total IgE
level was significantly higher in the former compared to the
latter.Equation of SNPs on PPARG gene in the study population.
otype Frequency Heterozygosity HWE
C/R R/R N
0 104 4 1288 0.043 0.083 0.294
4 358 36 1288 0.167 0.278 0.982
allele.
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Association of PPARG gene polymorphisms 1023Association of SNPs of the PPAR gene with the risk
of asthma
Two SNPs on the PPARG gene were genotyped for the
association study: þ34C>G (P12A) on exon 3 and
þ82466C> T (H449H) on exon 8. The minor allele
frequencies (MAF) of these two SNPs in the Korean pop-
ulation were 0.043 (þ34C> G) and 0.167 (þ82466C> T )
(Table 3). The genotype distributions of the loci were in
HardyeWeinberg equilibrium (p> 0.05; Table 3). Four
haplotypes were constructed, and two haplotypes with
a frequency >0.05 were used for the analysis. The
þ82466C> T SNP was found to be associated with asthma
development. The rare allele frequency was significantly
lower in patients with asthma compared to that of the
normal controls in a codominant model (OR: 0.78,
pZ 0.04). Haplotypes of PPARG were also associated with
the development of asthma (Table 4). The frequency of
PPARG-ht2 was significantly lower in the subjects with
asthma compared to the normal controls in both codomi-
nant and dominant models [pZ 0.01, pcorrZ 0.03, OR: 0.73
(0.57e0.94) and pZ 0.02, pcorrZ 0.03, OR: 0.71 (0.53e
0.94), respectively]. Conversely, the frequency of PPARG-
ht1 was significantly higher in those with asthma compared
to the normal controls in a codominant model [pZ 0.04,
pcorrZ 0.08, OR: 1.27 (1.01e1.6)].
Discussion
In the present study, we are the first to show that PPARG
polymorphisms are associated with the risk of developing
asthma. The frequency of PPARG-ht2 was significantly
lower, and the frequency of PPARG-ht1 was higher in the
subjects with asthma compared to the normal controls.
These data suggest that haplotype-2 may protect against
the development of asthma while haplotype-1 may be
linked to asthma predisposition. Recently, Palmer et al.
reported that two SNPs of PPARG are associated with the
risk of asthma exacerbation in Caucasian populations.10
Moreover, they observed no difference in allele frequency
from the normal controls. Thus, we tried to evaluate the
association of the two SNPs (þ34C> G and þ82466C> T )
with asthma development. However, since we did not
examine the exacerbation rate in our asthma cohort, we
were unable to replicate the link between asthma exacer-
bation rate and SNPs as demonstrated by Palmer et al.10
Because of the biological properties of PPARG as a regu-
lator of adipocyte differentiation and lipid metabolism,2
polymorphisms of the PPARG gene have been associatedwith
diabetes, obesity, and various metabolic syndromes.17 The
two common polymorphisms of PPARG were reported to
modify susceptibility to type 2 diabetes mellitus, obesity, and
subtypes of metabolic syndrome in Korean14,17 and Caucasian
populations.18,19 In accordance with these findings, we
excluded the subject with diabetes from our analysis and
adjusted the association analysis with BMI.
In addition to the metabolic effect, PPAR form hetero-
dimers with retinoid X receptors (RXR) and these hetero-
dimers regulate transcription of various genes that
participate in allergic inflammation and airway remodel-
ing.9,20 In addition to regulating inflammation and
1024 S.-H. Oh et al.immunity,21 PPARG also plays important roles in controlling
cell differentiation and fibrotic responses of the lung.22 In
comparison to normal subjects, subjects with asthma who
were not treated with steroids have increased expressions
of PPARG, particularly in the airway epithelium and smooth
muscle.9 PPARG is involved in a cross talk with glucocorti-
coid receptors or beta-2 adrenergic receptors.23 PPARG,
together with its synthetic agonists, appears to play an
important role in inflammation, and recent evidence indi-
cates that its expression is augmented in association with
features of early airway remodeling in patients with
asthma.9 Thus, PPARGþ 82466C> T may contribute to the
development of asthma via functional changes in the gene.
In summary, we genotyped two SNPs on PPARG, þ34C> G
(Pro12Ala) and þ82466C> T (His449His) and examined their
link to asthma development. Association analysis showed that
PPARGþ 82466C> T and PPARG-haplotypes were associated
with the development of asthma. Thus, the þ34C> G and
þ82466C> T polymorphisms present in the coding region of
PPARG may influence asthma predisposition via regulation of
gene expression. This information may contribute to the
development of new strategies for the diagnosis and control
of asthma.
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